Previous 10 | Next 10 |
Noteworthy events during the week of April 21 - 27 for healthcare investors. More news on: Galmed Pharmaceuticals Ltd., Horizon Pharma plc, Concert Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
-- The #RAREis™ Adoption Fund fills a critical gap for families seeking to provide a permanent home for children living with critical medical needs -- Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption...
Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association of Clinical Endocrinologists (AACE) 28...
- Company also awarded “Best Places to Work in Chicago” by Crain’s Chicago Business – Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to ...
Horizon Pharma plc (Nasdaq: HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results...
Selecta Biosciences ( SELB +2.8% ) initiates a six-month head-to-head clinical trial, COMPARE, evaluating lead drug SEL-212 versus Horizon Pharma's ( HZNP -0.2% ) Krystexxa (pegloticase) in adults with chronic refractory gout. More news on: Selecta Biosciences, Inc., Horizon Pharma...
Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be found here . PR New...
-- Total offering size of $345 million – -- Incremental $200 million borrowing capacity secured under new revolving credit facility -- Horizon Pharma plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 14,081,632 of its ordinary shares at ...
Phase III study of Teprotumumab Horizon Pharma ( HZNP ) reported top line results of its Phase III Teprotumumab clinical study for the treatment of TED on February 28, 2019. The Phase III trial was a confirmatory study of Phase II and was 21 weeks long, that included 83 patients across mul...
Horizon Pharma plc (NASDAQ: HZNP ) has priced its public offering of ~12.2M ordinary shares at $24.50 per share. Underwriters over-allotment is an additional ~1.8M shares. Closing date is March 11. More news on: Horizon Pharma plc, Healthcare stocks news, Stocks on the move, Read mor...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...